Transdermal iontophoretic delivery of selegiline hydrochloride, in vitro

References

• Alvarez-Figueroa MJ, González-Aramundiz JV. (2008). Passive and iontophoretic transdermal penetration of chlorpromazine. Pharm Dev Technol, 13: 271–275.
   PubMed Web of Science ®Google Scholar
• Anderson MC, Hasan F, McCrodden JM, Tipton KF. (1993). Monoamine oxidase inhibitors and the cheese effect. Neurochem Res, 18: 1145–1149.
   PubMed Web of Science ®Google Scholar
• Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C. (2007). Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol, 47: 1256–1267.
   PubMed Web of Science ®Google Scholar
• Barrett JS, DiSanto AR, Thomford PJ, Larsen EM, Palazzolo MJ, Morales RJ. (1997). Toxicokinetic evaluation of a selegiline transdermal system in the dog. Biopharm Drug Dispos, 18: 165–184.
   PubMed Web of Science ®Google Scholar
• Blackwell B, Marley E, Price J, Taylor D. (1967). Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry, 113: 349–365.
   PubMed Web of Science ®Google Scholar
• Bounoure F, Lahiani Skiba M, Besnard M, Arnaud P, Mallet E, Skiba M. (2008). Effect of iontophoresis and penetration enhancers on transdermal absorption of metopimazine. J Dermatol Sci, 52: 170–177.
   PubMed Web of Science ®Google Scholar
• Brand RM, Guy RH. (1995a). Iontophoresis of nicotine in vitro: pulsatile drug delivery across the skin?. J Control Release, 33: 285–292.
   Web of Science ®Google Scholar
• Brand RM, Guy RH. (1995b). Rapid transdermal delivery of nicotine by iontophoresis. J Control Release, 33: 285–292.
   Web of Science ®Google Scholar
• Burnette RR, Ongpipattanakul B. (1987). Characterization of the permselective properties of excised human skin during iontophoresis. J Pharm Sci, 76: 765–773.
   PubMed Web of Science ®Google Scholar
• Chrisp P, Mammen GJ, Sorkin EM. (1991). Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson’s disease. Drugs Aging, 1: 228–248.
   PubMedGoogle Scholar
• Delgado-Charro MB, Rodriguez-bayon AM, Guy RH. (1995). Iontophoresis of nafarelin: effects of current density and concentration on electrotransport in vitro. J Control Release, 35: 35–40.
   Web of Science ®Google Scholar
• Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P. (1978). Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the ‘cheese effect’. Psychopharmacology (Berl), 57: 33–38.
   Google Scholar
• Fang JY, Hung CF, Chi CH, Chen CC. (2009). Transdermal permeation of selegiline from hydrogel-membrane drug delivery systems. Int J Pharm, 380: 33–39.
   PubMed Web of Science ®Google Scholar
• Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS. (2006). Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, doble-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry, 67: 1354–1361.
   PubMed Web of Science ®Google Scholar
• Green PG, Hinz RS, Cullander C, Yamane G, Guy RH. (1991). Iontophoretic delivery of amino acids and amino acid derivatives across the skin in vitro. Pharm Res, 8: 1113–1120.
   PubMed Web of Science ®Google Scholar
• Hirvonen J, Guy RH. (1997). Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances. Pharm Res, 14: 1258–1263.
   PubMed Web of Science ®Google Scholar
• Howland RH. (2006). Transdermal selegiline: a novel MAOI formulation for depression. J Psychosoc Nurs Ment Health Serv, 44: 9–12.
   Web of Science ®Google Scholar
• Kasha PC, Banga AK. (2008). A review of patent literature for iontophoretic delivery and devices. Recent Pat Drug Deliv Formul, 2: 41–50.
   PubMedGoogle Scholar
• Kasting GB, Keister JC. (1989). Application of electrodiffusion theory for a homogeneous membrane to iontophoretic transport through skin. J Control Release, 8: 195–210.
   Web of Science ®Google Scholar
• Knoll J. (1986). The pharmacology of (−)deprenyl. J Neural Transm Suppl, 22: 75–89.
   PubMedGoogle Scholar
• Kolli CS, Banga AK. (2008). Characterization of solid maltose microneedles and their use for transdermal delivery. Pharm Res, 25: 104–113.
   PubMed Web of Science ®Google Scholar
• Pae CU, Lim HK, Han C, Neena A, Lee C, Patkar AA. (2007). Selegiline transdermal system: current awareness and promise. Prog Neuropsychopharmacol Biol Psychiatry, 31: 1153–1163.
   PubMed Web of Science ®Google Scholar
• Patkar AA, Pae CU, Masand PS. (2006). Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr, 11: 363–375.
   PubMed Web of Science ®Google Scholar
• Phipps JB, Gyory JR. 1992. Transdermal ion migration. Adv Drug Deliv Rev, 9: 137–176.
   Web of Science ®Google Scholar
• Phipps JB, Scott ER, Gyory JR, Padmanabhan RV. (2002). Iontophoresis. In Swarbrick J, Boylan JC, eds. Enyclopedia of Pharmaceutical Technology (pp. 1573–1587 ). 2 ed. New York: Marcel Dekker.
   Google Scholar
• Pickar D, Cohen RM, Jimerson DC, Murphy DL. (1981). Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity. Psychopharmacology (Berl), 74: 4–7.
   PubMed Web of Science ®Google Scholar
• Riviere JE, Heit MC. (1997). Electrically-assisted transdermal drug delivery. Pharm Res, 14: 687–697.
   PubMed Web of Science ®Google Scholar
• Tetrud JW, Koller WC. (2004). A novel formulation of selegiline for the treatment of Parkinson’s disease. Neurology, 63: S2–S6.
   PubMed Web of Science ®Google Scholar
• Wong KS, Lu CS, Shan DE, Yang CC, Tsoi TH, Mok V. (2003). Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson’s disease. J Neurol Sci, 216: 81–87.
   PubMed Web of Science ®Google Scholar